Cargando…

Exploiting Existing Molecular Scaffolds for Long-Term COVID Treatment

[Image: see text] Discovery and development of COVID-19 prophylactics and treatments remains a global imperative. This perspective provides an overview of important molecular pathways involved in the viral life cycle of SARS-CoV-2, the infectious agent of COVID-19. We highlight past and recent findi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Krishna, Lupoli, Tania J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269097/
https://www.ncbi.nlm.nih.gov/pubmed/32665808
http://dx.doi.org/10.1021/acsmedchemlett.0c00254
_version_ 1783541725901357056
author Kumar, Krishna
Lupoli, Tania J.
author_facet Kumar, Krishna
Lupoli, Tania J.
author_sort Kumar, Krishna
collection PubMed
description [Image: see text] Discovery and development of COVID-19 prophylactics and treatments remains a global imperative. This perspective provides an overview of important molecular pathways involved in the viral life cycle of SARS-CoV-2, the infectious agent of COVID-19. We highlight past and recent findings in essential coronavirus proteins, including RNA polymerase machinery, proteases, and fusion proteins, that offer opportunities for the design of novel inhibitors of SARS-CoV-2 infection. By discussing the current inventory of viral inhibitors, we identify molecular scaffolds that may be improved by medicinal chemistry efforts for effective therapeutics to treat current and future coronavirus-caused diseases.
format Online
Article
Text
id pubmed-7269097
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-72690972020-06-03 Exploiting Existing Molecular Scaffolds for Long-Term COVID Treatment Kumar, Krishna Lupoli, Tania J. ACS Med Chem Lett [Image: see text] Discovery and development of COVID-19 prophylactics and treatments remains a global imperative. This perspective provides an overview of important molecular pathways involved in the viral life cycle of SARS-CoV-2, the infectious agent of COVID-19. We highlight past and recent findings in essential coronavirus proteins, including RNA polymerase machinery, proteases, and fusion proteins, that offer opportunities for the design of novel inhibitors of SARS-CoV-2 infection. By discussing the current inventory of viral inhibitors, we identify molecular scaffolds that may be improved by medicinal chemistry efforts for effective therapeutics to treat current and future coronavirus-caused diseases. American Chemical Society 2020-06-03 /pmc/articles/PMC7269097/ /pubmed/32665808 http://dx.doi.org/10.1021/acsmedchemlett.0c00254 Text en Copyright © 2020 American Chemical Society This article is made available via the ACS COVID-19 subset (https://pubs.acs.org/page/vi/chemistry_coronavirus_research) for unrestricted RESEARCH re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Kumar, Krishna
Lupoli, Tania J.
Exploiting Existing Molecular Scaffolds for Long-Term COVID Treatment
title Exploiting Existing Molecular Scaffolds for Long-Term COVID Treatment
title_full Exploiting Existing Molecular Scaffolds for Long-Term COVID Treatment
title_fullStr Exploiting Existing Molecular Scaffolds for Long-Term COVID Treatment
title_full_unstemmed Exploiting Existing Molecular Scaffolds for Long-Term COVID Treatment
title_short Exploiting Existing Molecular Scaffolds for Long-Term COVID Treatment
title_sort exploiting existing molecular scaffolds for long-term covid treatment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269097/
https://www.ncbi.nlm.nih.gov/pubmed/32665808
http://dx.doi.org/10.1021/acsmedchemlett.0c00254
work_keys_str_mv AT kumarkrishna exploitingexistingmolecularscaffoldsforlongtermcovidtreatment
AT lupolitaniaj exploitingexistingmolecularscaffoldsforlongtermcovidtreatment